Latest Insider Transactions at Alkermes Plc. (ALKS)
This section provides a real-time view of insider transactions for Alkermes Plc. (ALKS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Alkermes plc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Alkermes plc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 20
2025
|
Samuel Joseph Parisi VP, Finance (Interim PAO) |
SELL
Open market or private sale
|
Direct |
1,327
-14.67%
|
$46,445
$35.69 P/Share
|
|
Feb 18
2025
|
Blair Curtis Jackson EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,950
-2.07%
|
$138,250
$35.9 P/Share
|
|
Feb 18
2025
|
Blair Curtis Jackson EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,896
+4.46%
|
-
|
|
Feb 18
2025
|
Iain Michael Brown SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,869
-1.34%
|
$65,415
$35.9 P/Share
|
|
Feb 18
2025
|
Iain Michael Brown SVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,354
+4.35%
|
-
|
|
Feb 18
2025
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,822
-1.45%
|
$98,770
$35.9 P/Share
|
|
Feb 18
2025
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
BUY
Exercise of conversion of derivative security
|
Direct |
6,354
+3.16%
|
-
|
|
Feb 18
2025
|
Christian Todd Nichols SVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,869
-2.22%
|
$65,415
$35.9 P/Share
|
|
Feb 18
2025
|
Christian Todd Nichols SVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,354
+7.02%
|
-
|
|
Feb 18
2025
|
Samuel Joseph Parisi VP, Finance (Interim PAO) |
SELL
Payment of exercise price or tax liability
|
Direct |
706
-7.24%
|
$24,710
$35.9 P/Share
|
|
Feb 18
2025
|
Samuel Joseph Parisi VP, Finance (Interim PAO) |
BUY
Exercise of conversion of derivative security
|
Direct |
2,033
+17.25%
|
-
|
|
Feb 18
2025
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,950
-5.92%
|
$138,250
$35.9 P/Share
|
|
Feb 18
2025
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,896
+11.76%
|
-
|
|
Feb 13
2025
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
144,419
-41.44%
|
$5,054,665
$35.02 P/Share
|
|
Feb 13
2025
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
144,419
+27.23%
|
$4,043,732
$28.26 P/Share
|
|
Feb 12
2025
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
204,921
-50.88%
|
$6,557,472
$32.98 P/Share
|
|
Feb 12
2025
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
199,196
+33.25%
|
$3,784,724
$19.69 P/Share
|
|
Feb 06
2025
|
Christian Todd Nichols SVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,399
-8.68%
|
$229,369
$31.39 P/Share
|
|
Feb 06
2025
|
Christian Todd Nichols SVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,565
+22.37%
|
-
|
|
Feb 06
2025
|
Richard F Pops Director and CEO, Alkermes plc |
SELL
Payment of exercise price or tax liability
|
Direct |
79,925
-5.83%
|
$2,477,675
$31.39 P/Share
|
|
Feb 06
2025
|
Richard F Pops Director and CEO, Alkermes plc |
BUY
Grant, award, or other acquisition
|
Direct |
190,640
+12.21%
|
-
|
|
Feb 06
2025
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
9,752
-4.92%
|
$302,312
$31.39 P/Share
|
|
Feb 06
2025
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
BUY
Grant, award, or other acquisition
|
Direct |
32,350
+14.03%
|
-
|
|
Feb 06
2025
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,083
-19.17%
|
$467,573
$31.39 P/Share
|
|
Feb 06
2025
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,393
+30.42%
|
-
|
|
Feb 06
2025
|
Blair Curtis Jackson EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,647
-5.54%
|
$330,057
$31.39 P/Share
|
|
Feb 06
2025
|
Blair Curtis Jackson EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,393
+15.18%
|
-
|
|
Feb 06
2025
|
Iain Michael Brown SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,514
-5.33%
|
$232,934
$31.39 P/Share
|
|
Feb 06
2025
|
Iain Michael Brown SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,565
+14.85%
|
-
|
|
Jan 30
2025
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
100,918
-69.5%
|
$3,229,376
$32.05 P/Share
|
|
Jan 30
2025
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
97,632
+18.72%
|
$2,147,904
$22.7 P/Share
|
|
Dec 09
2024
|
Cato T Laurencin Director |
SELL
Open market or private sale
|
Direct |
2,691
-10.47%
|
$83,421
$31.85 P/Share
|
|
Dec 09
2024
|
Cato T Laurencin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,691
+9.48%
|
$59,202
$22.52 P/Share
|
|
Dec 09
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
61,151
-56.24%
|
$1,956,832
$32.07 P/Share
|
|
Dec 09
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
48,997
+12.15%
|
$1,077,934
$22.7 P/Share
|
|
Dec 08
2024
|
Cato T Laurencin Director |
SELL
Payment of exercise price or tax liability
|
Direct |
958
-4.0%
|
$29,698
$31.46 P/Share
|
|
Dec 08
2024
|
Cato T Laurencin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,163
+14.8%
|
-
|
|
Dec 05
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,221
-13.37%
|
$285,851
$31.5 P/Share
|
|
Dec 04
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
14,349
-17.23%
|
$430,470
$30.77 P/Share
|
|
Nov 27
2024
|
Christian Todd Nichols SVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,208
-7.9%
|
$151,032
$29.15 P/Share
|
|
Nov 11
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
58,996
-41.46%
|
$1,769,880
$30.08 P/Share
|
|
Nov 11
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
43,058
+23.23%
|
$861,160
$20.03 P/Share
|
|
Nov 06
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,471
-9.54%
|
$303,659
$29.53 P/Share
|
|
Aug 03
2024
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
895
-0.54%
|
$24,165
$27.72 P/Share
|
|
Aug 03
2024
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
BUY
Exercise of conversion of derivative security
|
Direct |
2,014
+1.19%
|
-
|
|
Jun 29
2024
|
Brian P Mckeon Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,465
-5.01%
|
$35,160
$24.1 P/Share
|
|
Jun 29
2024
|
Brian P Mckeon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,104
+17.27%
|
-
|
|
Jun 29
2024
|
Nancy Lynn Md Snyderman Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,465
-24.0%
|
$35,160
$24.1 P/Share
|
|
Jun 29
2024
|
Nancy Lynn Md Snyderman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,104
+50.0%
|
-
|
|
Jun 29
2024
|
Frank Anders Wilson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,465
-5.54%
|
$35,160
$24.1 P/Share
|